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Introduction
Acute myeloid leukemia (AML) is a clinically and genetically 
heterogeneous clonal disease illustrated by the accumulation of 
acquired somatic genetic alterations in hematopoietic progenitor cells 
that modify normal mechanisms of self-renewal, proliferation and 
differentiation. The prognostic value of recently identified somatic 
mutations has not been systematically evaluated in a phase 3 clinical 
trial of treatment for AML. However, non-random clonal chromosome 
aberrations such as balanced translocations, inversions, deletions, 
monosomies, and trisomies are detectable in the leukemic blasts 
of approximately 55% of adults with AML [1]. These chromosome 
changes have contributed to the classification of the disease and in the 
past they have been recognized as the most important prognostic factor 
for achievement of complete remission (CR), risk of relapse, and overall 
survival (OS) [2,3]. However, molecular pathogenesis of disease has 
not yet been completely defined and treatment stratification is difficult, 
especially for patients with intermediate-risk AML with a normal 
karyotype. The molecular markers span a wide spectrum of biological 
functions and range from activating mutations such as internal tandem 
duplications of the Fms-like tyrosine kinase3 (FLT3) gene, (FLT3-ITD) 
with the insertion of hundreds of nucleotides to point mutations within 
the RAS proto-oncogenes [4], receptor tyrosine kinase (KIT) mutation 
in gene that encodes a receptor tyrosine kinase, Janus kinase 2 (JAK2) 
mutation, myeloid-lymphoid or mixed-lineage leukemia (MLL) gene 
and the Wilms tumor (WT1) gene in AML. Further examples are 
alterations of genes encoding transcription factors such as CCAAT/
enhancer binding protein alpha (CEBPA) [5,6] or mutations interfering 
with tumor suppressor pathways such as Nucleophosmin (NPM1) 
mutations [7] consisting of four base pair insertions in most cases. The 
Runt-related transcription factor1 (RUNX1) gene is another candidate 
targeted by chromosomal rearrangements or intragenic mutations in 
acute leukemia [8] has significantly improved our understanding of 
leukemogenesis. Another, class of genes encoding epigenetic modifiers, 
including Isocitrate dehydrogenase 1 (IDH1), Isocitrate dehydrogenase 
2 (IDH2), Enhancer of zeste homolog 2 (EZH2) and Polo like kinases 
1 (PLK1) appears to play a major role in AML Pathogenesis [9]. 
The characterization of these gene mutations which are involved 
in leukemogenesis has provided insights into the mechanisms of 
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Abstract
Acquired genetic alterations which include balanced and unbalanced chromosome aberrations and 
submicroscopic gene mutations and changes in gene expression strongly influenced by pretreatment clinical 
features and prognosis of adults patients with acute myeloid leukemia (AML). Cytogenetic profiling separate AML 
patients into three broad prognostic groups: favorable, intermediate and adverse. The cytogenetic risk classifications 
vary to some extent for younger adult patients and for those aged 60 years or older. In many cases, patients with 
specific cytogenetic rearrangement such as those with a normal karyotype or those with either RUNX1-RUNX1T1 
or CBFB-MYH11 feature of core-binding factor (CBF) can be further subdivided into prognostic categories 
depend on the presence or absence of specific gene mutations or changes in gene expression. Advancement in 
the understanding of cancer genetic and discovery of recurrent mutations in AML provide opportunity to develop 
targeted therapies and improve the clinical outcome. The identified gene mutations, mainly targetable lesions are 
gain of function mutations of JAK2 and cKIT and FLT3 in APL have been associated with clinical features and/
or outcome of patients with these AML subtypes. These data emphasize the significance of genetic testing for 
common translocations for diagnosis, prognosis and increasingly targeted therapy in acute leukemia. Notably, 
these several molecular genetic alterations constitute a variety of diverse new targets for salvage therapies. These 
approaches intend to develop targeted treatment concepts that depend on interference with molecular genetics or 
epigenetic mechanisms. This report provides an overview on characteristic gene mutations, discuss their biological 
functions and Prognostic significance, which serve as basis for selected therapy approaches now or might represent 
options for such approaches in the future and expected to have a role in treating AML subtypes with characteristic 
molecular alterations.
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leukemogenesis. From a clinical viewpoint there are two important 
aspects. First, some of these gene mutations have emerged as important 
prognostic and predictive markers. Second, novel therapies are now 
being developed that targets these molecular changes. It is therefore 
anticipated that an improved molecular characterization of AML 
not only allows a more detailed sub-classification and more exact 
prognostic predictions in many patients, but also provides the basis for 
future therapeutic approaches. Whereas targeted therapy in AML was 
previously mainly restricted to the application of all-trans retinoic acid 
(ATRA) in patients with acute pro-myelocytic leukemia (APL) with 
the t(15;17)/PML-RARA, deeper insights in the variety of molecular 
markers, signaling pathways, and cooperating leukemogenic processes 
opened new perspectives for molecular targets that hopefully will lead 
to more individualized treatment concepts. The present review is an 
update of the distinct gene mutations, discuss their biological functions 
and clinical significance, which are expected to have a role in treating 
distinct subtype of AML with characteristic druggable mutations. 
Mechanism of Leukemogenesis
Several studies reveal that different genetic alterations cooperate in 
leukemogenesis [10,11]. Data from murine models and human AML 
cases suggest that a single mutation is not sufficient to cause AML 
[12]. For instance, the RUNX-RUNX1T1 and CBFB-MYH11 chimeric 
oncogenes, resulting from t(8;21) and inv(16)t(16;16) respectively, 
block myeloid differentiation in murine models but they do not cause an 
overt leukemic phenotype. On the other hand, rare germline mutations 
have been described in RUNX1 and CEBPA that predispose affected 
individuals to the progression of AML. Constitutional heterozygous 
loss-of function mutations in the transcription factor RUNX1 have 
been associated with familial platelet disorder with propensity to 
AML. In these individuals, overt leukemia likely develops upon the 
somatic acquisition of further mutations in hematopoietic progenitor 
cells. In addition, evidence comes from human disease, since in the 
majority of AML cases more than one genetic change can be detected. 
Somatically acquired mutations have been identified in several genes 
in cytogenetically normal CN-AML in last decade: NPM1 gene, FLT3 
gene, CEBPA gene, MLL gene, the neuroblastoma RAS viral oncogene 
homolog NRAS gene, WT1gene, and RUNX1 gene [13,14]. These gene 
mutations are most prevalent in CN-AML, however, they also occur in 
AML with abnormal karyotypes.
The different classes of mutations which cooperate in 
leukemogenesis fall into broadly defined complementation groups. One 
group (class I) comprises mutations which activate signal transduction 
pathways resulting in enhanced proliferation and/or survival of 
leukemic progenitor cells such as mutations leading to activation of 
the receptor tyrosine kinase FLT3 or the RAS signaling pathway. 
The second complementation group (class II) comprises mutations 
that affect transcription factors or components of the transcriptional 
co-activation complex, resulting in impaired differentiation and/
or aberrant acquisition of self-renewal properties by hematopoietic 
progenitors. Prominent examples are the recurring gene fusions 
resulting from t(8;21), inv(16)/t(16;16), t(15;17), as well as mutations 
in CEBPA, MLL, and possibly also NPM1 [15,16]. The third group 
(class III) is distinguished from the already proposed class I and class II 
genetic abnormalities. This group comprises genes encoding epigenetic 
modifiers, including DNMT3A, IDH1, IDH2 and EZH2, appears to 
play a major role in AML pathogenesis [9]. Interestingly, most of the 
mutations belonging to this class seem to be associated with a poor 
outcome in patients and more commonly observed in older patients 
with the disease. They may thus provide a genetic explanation for the 
worse treatment effects found in older as opposed to younger patients, 
even in patients with favorable cytogenetic or genetic characteristic 
(Table 1).
NPM1 Mutations
NPM1 mutations are the most frequent genetic alteration in adult 
AML and found in 45-64% of CN-AML [17]. This mutation is much 
less common 2-8% in pediatric AML and about 7.5% in younger 
median age AML cases [13,14,18,19]. Notably, Incidence of the NPM1 
mutations is age-dependent as the mutation has not yet been identified 
in children younger than 3 years old, whereas the frequency is 10-
19% in children older than 3 years and exceeds 30% in children older 
than 10 years [20,21]. In 2005, abnormal cytoplasmic localization of 
the NPM1 protein shown by immunohistochemical analysis led to 
the discovery that in a substantial proportion of AML cases, there is 
abnormal cytoplasmic localization of the NPM1 protein [7]. This 
mislocalization is caused by mutations in exon 12 of the gene which 
result in loss of tryptophan residues normally required for NPM1 
binding to the nucleoli and in the formation of an additional nuclear 
export signal motif at the C-terminus. This pleiotropic nucleolar 
protein that shuttles across cytoplasm and nucleoplasm and regulates 
among others centrosome maturation and the tumor suppressor 
ARF-p53 pathway [22,23].
In adult AML, more than 40 diverse mutational subtypes of 
NPM1 are present, which mostly consist of four base pair insertions 
[7]. Subtype A, NPM1 mutation (TCTG duplication) consist of three 
quarter of mutated cases, whereas two alternate 4-bp insertions 
at the same position such as type B (CATG insertion) and type D 
(CCTG insertion) comprise an additional 15% of mutated cases. 
The distribution of the different mutation classes is also different in 
adults and children: adults show most frequently the mutational 
subtype A whereas type B insertion is much frequent in pediatric cases 
[20,21]. Each of these variants has been targeted using allele-specific 
amplification to detect minimal residual disease (MRD) and to predict 
relapse [24]. while, lack of mutation in 10% of relapsed AML patients 
limits the reliability of these allele-specific assays for monitoring tumor 
burden over time [24]. NPM1 mutations are associated with other 
recurrent genetic changes, secondary chromosome abnormalities such 
as +8,+4, del(9q) and additional gene mutations, most frequently in 
FLT3 and IDH1 [25-27]. 
NPM1 mutations cooperate with other gene mutations in 
leukemogenesis. However, the leukemogenic mechanism of the NPM1 
mutations is not yet fully understood, as the NPM1 protein is also 
involved in other cellular processes such as the regulation of centrosome 
function or the processing of pre-RNA molecules [17]. Cytoplasmic 
mutant NPM1 contributes to AML development by inactivating p19Arf 
through delocalization of the tumor suppressor protein. This results in 
reduced p19Arf activities, both p53-dependent [Mouse double minute 
2 homolog (MDM2) and cyclin-dependent kinase inhibitor 1 (p21cip1) 
induction] and p53-independent (sumoylation of NPM). Stability of 
p19Arf is compromised when coupled with NPM1 mutant, which may 
lead to weaker control of the p53-dependent cell-cycle arrest [28,29]. 
Mutated NPM1 bounds to nuclear factor kappa-light-chain-enhancer 
of activated B cells (NF-kappaB) and dislocates it in the cytoplasm, 
leading to its inactivation. This inactivation of NF-kappaB is thought to 
be responsible for the high response rates of AML with NPM1mutant 
to chemotherapy [30,31].
NPM1 Prognostic Relevance
NPM1 protein has been associated with several clinical and 
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biological features. In univariate analysis, data on the prognostic 
impact of NPM1 mutations have been somewhat controversial with 
some studies showing a significant effect on CR rate, relapse-free 
survival (RFS), and event-free survival (EFS) [32,33], while other 
studies did not reveal significant differences in these parameters 
[34,35]. Approximately 40% of patients with NPM1 mutations also 
carry FLT3- ITD, and it is linked with favorable prognosis when FLT3-
ITD is absent and intermediate prognosis when FLT3-ITD is present 
[36]. Recent study showed that patients with FLT3-ITD and NPM1 
mutations have an improved CR, DFS and OS compared with those 
who only have the FLT3-ITD aberration [37].
NPM1 Therapeutic Implications
Patients having NPM1 mutation do not necessarily benefit from 
allogeneic human stem cell transfer (HSCT) following conventional 
anthracycline and cytarabine based induction therapy and older 
patients with this mutation without FLT3-ITD might benefit from 
adding ATRA to their chemotherapy regimen [18,38]. Recently 
it was reported that clinical course of patients with refractory or 
relapsed FLT3-ITD+/NPM1+ AML, achieved significant response upon 
sorafenib, FLT3 inhibitor and ATRA combination [39].
FLT3 Mutations
FLT3 is a member of class III tyrosine kinase receptor family, 
which also includes colony stimulating factors (c-FMS), c-KIT, and 
platelet derived growth factor receptor (PDGFR) [40]. The FLT3 gene 
encodes a 993 amino acid protein in humans, which is composed 
of an immunoglobulin-like extracellular ligand-binding domain, a 
transmembrane domain, a Juxtamembrane (JM) dimerization domain 
and a cytoplasmic domain with a split tyrosine kinase motif [41]. It 
is expressed in immature hematopoietic cells, placenta, gonads, 
brain, and in lymphohematopoietic organs such as the liver, spleen 
and the thymus [42]. FLT3 expression in the normal bone marrow is 
restricted to early progenitors, including CD34+ cells with high levels 
of expression of CD117 (c-KIT), and committed myeloid and lymphoid 
progenitors with variable expression in the more mature monocytic 
lineage [43]. It is also expressed at high levels in many hematologic 
malignancies including most of AML subtypes, B-precursor cell acute 
lymphoblastic leukemia (ALL), some T-cell ALLs, and chronic myeloid 
leukemia (CML) in blast crisis [44,45].
FLT3 receptor exists in a monomeric unphosphorylated status 
and turns activated when bound by its FLT3 ligand, which promotes 
its unfolding and homodimerization. Homodimerization of FLT3 
switches on its tyrosine kinase activity and recruits a number of 
intracellular proteins to its intracellular domain. Each protein becomes 
activated and a phosphorylation cascade starts resulting in activation 
of secondary mediators such as MAP kinase, STAT, and AKT/PI3 
kinase signal transduction pathways, which are transported to the 
nucleus by HSP90, where they regulate transcription of several genes, 
which participate in differentiation, proliferation, and apoptosis 
[46]. FLT3 mutations occur in about 25-30% of AML patients and 
confer a poor prognosis [47]. Recent study showed the lower overall 
frequency of FLT3 mutations i.e. (18.55%) than most of the previously 
reported studies [48]. The lower frequency of FLT3 mutations may be 
due to differences in the sizes of examined groups or might be due to 
population genetics and environmental factors. 
Two major types of FLT3 mutations, FLT3-ITD and FLT3-TKD 
promotes constitutive phosphorylation of the FLT3 protein thereby 
impairing normal hematopoiesis and contributing to leukemogenesis 
[49].
FLT3-ITD
The most common mutation of FLT3 in AML is FLT3-ITD. It 
results from a duplication of a fragment within the JM domain coding 
region encoded by exons 14 and 15 of FLT3. JM domain is essential for 
kinase autoinhibition and disruption of this domain by ITDs of various 
sizes and insertion sites is detectable in 28-34% of CN-AML, whereas 
JM point mutations are rare [14,18]. Segmental duplication of the JM 
domain of FLT3 promotes auto-dimerization and autophosphorylation 
of the receptor, which turns it constitutively phosphorylated and 
activating AKT [50]. Some of the effects of FLT3-ITDs are unique to 
the mutated receptor, cellular proliferation of FLT3-ITD transduced 
cells is mediated by RAS and STAT5 pathways, while ligand-induced 
FLT3-wild type (WT) activation does not lead to STAT5 activation and 
Mutations Role of Mutation Frequency (%) Co-occurrence with other mutation Prognostic Rationale
NPM1
4 base pair insertion. 
Mutation in Exon 12 of 
gene
45-64% in CN-AML, 2-8% in 
paediatric AML FLT3 and IDH1 controversial
FLT3 inhibitors and ATRA combination, 
Sorafenib
FLT3-ITD JM domain of exon 14-15
28-34% in CN-AML, 5-10% in age 
5-10 yrs. >35% in adult AML
Rarely coexist with FLT3-
TKD unfavourable
Sorafenib, Quizartinib (AC220), 
Lestaurtinib (CEP701), Midostaurin 
(PKC412), Pacritinib (SB1518)
CEBPA
N- and C- terminal 
mutation in intronless 
gene
7% in CN-AML FLT3-ITD favourable Histone deacetylase (HDAC) inhibitors, targeting Sox4 gene
MLL-PTD Fused exon 9 and 3 5-10% in CN-AML FLT3-ITD, CEBPA, NMP1 unfavourable
Combination of depsipeptide 
and decitanib, Human stem cells 
transplantation (HSCT)
KIT Gain of function 6-48% in adult AML, 17-41% paediatric CBF-AML Unknown unfavourable
Imatinib, Sunitinib and dasatinib, 
APcK110
RAS Point mutations 10-25% of AML cases Unknown controversial Cytarabine, Farnesyltransferase Inhibitor
RUNX1 Translocation, point mutation 15-20% of AML cases Unknown controversial Epigenetic therapeutic approach
IDH1/2 Loss of function ~30% in CN-AML cases NMP1 and CEBPA unfavourable unknown
JAK2 Gain of function Over all 3.2% in AML cases KIT and FLT3 controversial Ruxolitinib, Pacritinib, lestaurtinib,
EZH2 Transcription of epigenetic regulators 21-30% in denovo AML unknown controversial
3-3-Deazaneplanocin A (DZNep), 
EPZ005687 and GSK126
Table 1: Mutation roles, occurrence, co-occurrence with other AML mutations, their prognostic value and molecular targeted therapies of these distinct mutations.
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inhibit STAT5 DNA binding [51]. Nakao et al. first described FLT3-
ITD in a high proportion of patients with AML [52]. FLT3-ITD is rare 
in infant AML, but increases to 5-10% in age 5-10 years, 13-27% in 
young adults, and more than 35% in AML patients older than 55 years 
[48,53,54]. 
FLT3 tyrosine kinase domain mutations (FLT3-TKD)
Mutations in the TKD mostly affect the activation loop in the 
carboxy-terminal lobe. These point mutations, small insertions, or 
deletions mainly involve codons 835 and 836 in 11-14% of CN-AML 
[14,18]. While the frequency of FLT3-TKD in some studies found to 
be low approximately 4-7% [48,55]. Point mutations or insertions 
located at other codons in the TKD are rare. FLT3-TKD is the second 
most common type of FLT3 mutations found in AML and they can 
rarely coexist with FLT3-ITD. Based on in vitro and in vivo studies, 
FLT3-TKD promotes ligand-independent proliferation through 
autophosphorylation and constitutive receptor activation, similar 
to that of FLT3-ITD but there are significant biological differences 
between the two types of FLT3 mutations. They promote activation 
of different downstream effectors, and trigger different biological 
responses [49].
FLT3-ITD Prognostic Relevance
FLT3 mutations are of major relevance due to their prognostic 
impact and because constitutively active FLT3 is an attractive target 
for molecular therapy. Previous Studies have shown that presence of 
FLT3-ITD is an independent prognostic factor for worse outcome 
in AML [56]. Kottaridis et al. (2001) studied the prevalence and 
prognostic relevance of FLT3-ITD in a cohort of more than 850 
adult AML patients. They found FLT3- ITD in 27% of patients and 
confirmed previous studies reporting that FLT3-ITDs were associated 
with leukocytosis and normal karyotyping [57]. In their study, AML 
patients with FLT3-ITD had a lower remission rate, higher relapse rate, 
and worse survival. Multivariable analyses showed that FLT3-ITD was 
the most significant prognostic factor with respect to relapse rate and 
DFS. In other studies, survival for patients with FLT3-ITD was 20-30% 
compared to 50% for those without FLT3-ITD and allelic variations in 
patients with FLT3-ITD appeared to influence outcome [53]. Similar 
work in other studies has revealed differences in clinical outcome for 
those with differing allelic ratios [36].
FLT3 Therapeutic Implication
FLT3 tyrosine kinase is considered to be the most reasonable 
targetable protein in AML [9]. Several potent FLT3 kinase inhibitors are 
currently in development for AML that harbors FLT3-ITD mutations 
and former results of FLT3 inhibitors in clinical advancement have 
already produced encouraging and clinical significant activity [9]. 
Sorafenib is among the most extensively studied first generation 
FLT3 inhibitors. It has shown to particularly decrease the percentage 
of leukemia blasts in the peripheral blood (7.5% from 81%) and the 
bone marrow (34% from 75.5%) of AML patients have FLT3-ITD but 
not in patients lacking this mutation [58]. It has also have activity in 
FLT3-ITD-positive AML relapsing patients after allogeneic stem cell 
transplantation [59]. However, resistance development against TKIs 
is a well-known therapeutic dilemma. Several researchers focus their 
attempts in forming strategies to avert or repeal ‘acquired’ resistance 
against TKIs. Moreover, in vitro data have reported that the anti-
leukemic function of TKIs can be enhanced when combined with the 
proapoptotic small molecule Nutlin-3, which hampers the MDM2/p53 
interaction [60]. Moreover, fluvastatin, a drug employ for the treatment 
of hypercholesterolemia, has revealed potency to reverse resistance 
and enhanced function of sorafenib [61]. Quizartinib (AC220), a 
second-generation FLT3 inhibitor, which shows low nanomolar 
potency, good bioavailability and excellent kinase selectivity [62]. 
Early clinical outcomes of quizartinib were promising. They exhibited 
meaningful reductions in marrow blasts in a considerable proportion 
of patients having both refractory and relapsed FLT3-ITD+ AML [63]. 
Lestaurtinib (CEP701) which is a dual FLT3 and JAK2 inhibitor has 
revealed activity as monotherapy in AML, even if, it produced high 
remission rate, it did not remain successful in increasing survival in 
combination with cytarabine and idarubicin in young patients having 
relapsed or refractory AML [64]. A semi-synthetic multitargeted 
tyrosine kinase inhibitor, Midostaurin (PKC412) , has shown activity 
as monotherapy in FLT3-mutant and wild-type AML patients and 
high CR and survival rates when transferred in combination with 
standard chemotherapy in newly diagnosed young adults AML [65]. 
A novel potent JAK2/FLT3 inhibitor, Pacritinib (SB1518), has shown 
promising activity and clinical advantaged in refractory AML patients 
treated in a phase I clinical trial [66]. Pacritinib in combination with 
pracinostat (SB939), an oral HDAC inhibitor demonstrated synergy in 
decreasing tumor development and JAK2 and FLT3 signaling [67]. An 
additional oral multikinase inhibitor that has exhibited antileukemic 
activity in preclinical trail is TG02 that hampers CDKs 1, 2, 7 and 9 
together with JAK2 and FLT3 [68].
CEBPA Mutations
CEBPA is an intronless gene located at chromosome 19q13.1 that 
encodes for a basic region leucine zipper transcription factor, which 
can bind as a homodimer to certain promoters and enhancers but can 
also form heterodimers with related proteins CEBP-β and CEBP-γ [69]. 
CEBPA functions as key regulator of granulocytic differentiation. Two 
major types of heterozygous CEBPA mutations, sporadic and familial 
contribute to leukemogenesis by promoting proliferation and blocking 
differentiation of myeloid lineage [70]. Nonsense mutations affecting the 
N-terminal region of the molecule prevent expression of the full-length 
CEBPA protein, thereby up-regulating the formation of a truncated 
isoform with dominant-negative properties; and in-frame mutations in 
the C-terminal basic region-leucine zipper domain resulting in CEBPA 
proteins with decreased DNA-binding or dimerization activity. N- and 
C-terminal mutations often occur simultaneously [71].
CEBPA-mutated AML usually displays classical features of 
AML with or without cell maturation but some cases may show 
monocytic or monoblastic features. Myeloid-associated antigens 
HLA-DR and CD34 are usually expressed, as is CD7 in a significant 
proportion of patients. About 70% of cases have normal karyotype 
and approximately 25% carry concomitant FLT3-ITD mutations 
[6]. Interestingly, by using gene expression profiling, a subgroup of 
AML could be defined that exhibits a transcriptional signature which 
resembles that of AMLs with CEBPA mutations, while lacking such 
mutations [72]. In most, but not all, of these AMLs, the CEBPA gene 
was silenced by promoter hypermethylation. Moreover, this subset of 
AML showed a strong association with putatively activating mutations 
in the NOTCH1 gene. CEBPA encodes a transcription factor important 
in neutrophil differentiation. mutation down-regulates the HOX gene 
expression leading to decreased expression of myeloid differentiation 
factors, induction of miR181, and decreased expression of erythroid 
differentiation gene leading to elevated hemoglobin [73]. Recently, 
CEBPA target genes, the glycolytic enzyme hexokinase 3 (HK3) and 
the krüppel-like factor 5 (KLF5 )transcription factor, identified as 
novel CEBPA-regulated genes in AML and during APL differentiation 
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underlining their tumor suppressor role in AML as well as their 
function in granulopoiesis [74].
CEBPA Prognostic Relevance
Several studies have shown that CN-AMLs with CEBPA mutations 
portend a good prognosis than does wild type CEBPA in AML with 
FLT3-ITD [75]. Despite the absence of FLT3-ITD, the division of 
patients with triplet negative results (negative for CEBPA mutation, 
NPM1 mutation and FLT3-ITD) do poorly and may be considered for 
allogenic transplant [18]. However, coexistence of NPM1 mutations 
with monoallelic CEBPA mutations was shown to be associated with 
prolonged survival in CN-AML patients [76]. Hereditary predisposition 
is a noteworthy point related to CEBPA. Germ-cell mutations appear to 
occur in 7% of patients with CN AML and myeloid precursor cells from 
healthy individuals carrying single germ-line CEBPA mutation may 
evolve to overt AML by acquiring a second sporadic CEBPA mutation 
[77]. Adult AML with CEBPA mutation is also a provisional entity in 
the world health organization (WHO) current classification.
CEBPA Therapeutic Implication
Therapeutic recommendations are similar to those for AML 
with mutated NPM1without FLT3-ITD, that is, standard induction 
chemotherapy followed by three to four cycles of high-dose cytarabine 
[78]. Furthermore, AML with double CEBPA mutations may not 
benefit from (HSCT); however, this statement is recently not confirmed 
by data, but by assumption that in general, patients with favorable-risk 
AML do not get advantage from this approach in first CR. Due to low 
incidence of the mutation, effects of novel antileukemic agents and of 
allogeneic HSCT in this class of AML can only assessed in intergroup 
trials or in retrospective large meta-analyses. Moreover new research 
identified histone deacetylase (HDAC) inhibitors are able to reactivate 
the expression of the CEBPA signature and enhance the growth of 
healthy blood cells, showing the HDAC inhibitors as potential drug 
targets for the treatment of the AML subtype [79]. Another finding 
identified and validate a gene Sox4, molecular target for CEBPA 
mutations, targeting Sox4 effectively inhibits the major leukemogenic 
phenotypes in human mutated CEBPA AML samples [80].
MLL-Partial tandem duplication (PTD) Mutations
MLL gene encodes a protein that plays an essential role in 
early development and hematopoiesis by working as a histone 
methyltransferase and transcriptional co-activator. One of its domains, 
the SET domain, mediates methylation of ‘Lys-4’ of histone H3 
(H3K4me) complex and acetylation of ‘Lys-16’ of histone H4. H3K4me 
mediates epigenetic transcriptional activation of specific target genes, 
including many of the HOX genes [81]. Aberrant expression of 
MLL is usually associated with leukemogenesis [82]. MLL-PTD was 
considered the first molecular aberration that has influence on clinical 
outcome of cytogenetically normal adults with de novo AML [83]. 
These duplications consist of an in-frame duplication of MLL exons. 
MLL-PTDs are named according to the fused exon 9 and exon 3. Some, 
PTD seem to be generated by mispairing of Alu elements, which are 
repetitive regions with high homology [84]. These intragenic MLL 
abnormalities, which occur mainly in CN-AML, detected in about 5 
to 10% of these patients and usually involve exon 5 to exon11 or, less 
commonly, exon 5 to exon12 and frequent in those AML patients with 
trisomy 11 [14,25]. In about 30 to 40% of AML patients with MLL-
PTD may have FLT3-ITD [32] whereas CEBPA or NPM1 mutations 
are rarely found together with MLL-PTD [32]. Patients with MLL-
PTD do not differ significantly from those without this mutation with 
regard to pretreatment characteristics. However, their CR duration is 
significantly shorter than that of patients without the MLL-PTD [85]. 
MLL Prognostic Relevance
MLL aberrations, both chromosomal and intragenic, are 
prognostically worse [86]. A multivariable analysis that did not include 
other molecular genetic markers revealed MLL-PTD status as the only 
prognostically significant factor for CR duration [85]. Several studies 
revealed that MLL has been associated with a poor prognosis alone and 
when associated with FLT3-ITD [12].
MLL Therapeutic Implication
MLL wild-type allele transcription can be re-activated in vitro 
by the combination of depsipeptide, a histone deacetylase inhibitor, 
and decitabine (5’-aza-2’-deoxycytidine), a DNA methyltransferase 
inhibitor, and this shows to enhanced apoptosis [87]. These studies 
suggest that MLL-PTD- positive patients might benefit from therapy 
that includes DNA methyltransferase and/or histone deacetylase 
inhibitors. Nevertheless, until such molecular targeted therapy is 
demonstrated to be clinically effective in these patients, HSCT seems 
to be the best therapeutic approach for MLL-PTD positive patients 
[85]. Another finding indicate that liposomal bortezomib as a single 
and novel therapeutic agent to eliminate AML in a MLLPTD/wt:FLT3ITD/wt 
murine model [12]. However, further research is needed to evaluate the 
effect of novel agent for the treatment of human AML disease. Recent 
research indicate that epigenetic modifiers, such as lysine-specific 
demethylase 1 (LSD1) inhibitors, are potentially useful for treating 
MLL-rearranged AML and an in vivo study is now required to confirm 
this finding [88]. 
WT1 Mutations
Mutations in the WT1 gene in AML were first reported in 1998 
by King-Underwood and Pritchard-Jones [89]. WT1 gene, located on 
chromosome 11p13, encodes a zinc-finger DNA binding protein. Since 
it might function as tumor suppressor gene or as oncogene, activation 
duality is assumed as it could either be involved in transcriptional 
activation or in suppression of differentiation of myelomonocytic cells 
[90]. Therefore, disruption of WT1 function by mutation of the gene 
could either promote proliferation or induce a block in differentiation. 
WT1 is highly expressed in various leukemia types, particularly in 
AML [91]. In study of 70 patients with CN-AML by Summers et al. 
WT1 mutations were detected in 10% of cases [92]. Mutations of 
WTI in relation AML consisted of insertions or deletions that mainly 
clustered in exons 7 and 9 [93]. Preliminary data resulting from two 
small studies on heterogeneous patient populations suggest that WT1 
mutations may be associated with induction failure and their role in 
leukemogenesis is still not completely defined [92,94]. According to 
retrospective study WTI detected 8.3% (70 of 842) of pediatric AML 
cases and it is associated with shorter OS and EFS as well as high risk 
of relapse [93]. 
WTI Prognostic Relevance
Transcriptional dysregulation of WTI gene confer poor prognostic 
information [93]. However, the prognostic impact of WT1 mutations 
needs to be evaluated in larger patient cohorts and within the context 
of other molecular markers. Further insight into the roles that this gene 
plays in leukemogenesis may eventually pave the way for molecular 
targeted therapies.
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KIT Mutation
KIT encodes a receptor tyrosine kinase that expressed in both 
hematopoietic progenitor cells and AML blasts [95]. Upon binding 
of the ligand stem cell factor to c-kit, phosphorylation of several 
cytoplasmic proteins occurs and pertinent downstream pathways get 
activated. Those pathways are the JAK/ STAT pathway, the PI-3 kinase 
pathway and the MAP kinase pathway [96]. Mutations in c-KIT receptor 
result in constitutive phosphorylation and activation of the receptor in 
absence of the ligand. Gain of function mutations in KIT have been 
found in 2-8% of AML overall and in a third of the CBF AML [97]. KIT 
mutations encoded by exon 8 located in the extracellular portion of the 
receptor or KIT D816 mutations in the activation loop at codon 816 
encoded by exon 17 are detectable in about 6%-48% in adult and 17-
41% with pediatric CBF AML cases [98]. Recent progress in KIT D816 
mutation analysis showed that in peripheral blood it detected in (78 of 
83) systemic mastocytosis (94%) and (3 of 4) cutaneous mastocytosis 
patients (75%) [99]. 
KIT Prognostic Relevance
Several studies have evaluated the prognostic significance of 
KIT mutations in CBF AML [100]. D816V mutation is associated 
with a worse prognosis in AML with t(8;21) RUNX1-RUNX1T1, in 
contrast good prognosis normally linked with t(8;21) [101,102]. In 
inv(16)/t(16;16), a study by the Cancer and Leukemia Group B on a 
larger patient cohort showed that KIT mutations are associated with a 
higher cumulative incidence of relapse, this difference was mainly due 
to the effect of KIT exon 17 mutations [100]. In multivariable analysis, 
KIT mutation was an adverse prognostic factor for OS. These results 
need independent confirmation in large patient cohorts that have 
received uniform treatment. 
KIT Therapeutic Implication
Mutant KIT alleles represent a potential target for molecular 
therapies. Multi-kinase inhibitors such as imatinib, sunitinib and 
dasatinib beside their indications for the treatment of CML, renal 
cancer respectively, have also been certified for the treatment of 
gastrointestinal stromal tumors and AML, as they effectively inhibit 
mutated c-KIT, which is the characteristic molecular anomaly in these 
tumors [103]. Notably, not all c-KIT mutations respond to the same 
agent, for instance, exon 8 and the exon 17 N822 c-KIT mutations 
but not the D816 are sensitive to imatinib in vitro, hence evaluation 
of the exact c-KIT mutational status is crucial and may have direct 
therapeutic consequences. Early clinical studies with imatinib in a 
small number of patients with refractory AML did not show beneficial 
results [104]. However, when tested in c-KIT positive AML patients 
results were more promising [105]. Several studies have investigated 
the activity of imatinib alone or in combination with chemotherapy 
in c-KIT positive AML patients and results are anticipated. Small 
molecules such as SU5416 and SU6668 have activity against c-KIT [106] 
although neither is selective. A novel KIT inhibitor, APcK110 with 
potent proapoptotic and antiproliferative activity in AML cell lines and 
primary samples while in an AML xenograft mouse model it was found 
to extend survival [107]. In addition, KIT inhibition with dasatinib 
shows a promising approach to targeted therapy in t(8;21)AML and 
clinical trials are presently evaluating its clinical application. Recent 
study identified TKI-resistant states of transient nature that associated 
with modifications in KIT expression and can be reversed upon brief 
inhibitor removal. These findings revealed that discontinuing treatment 
retains dasatinib sensitivity in KITmut AML cells [108].
RAS Mutations
RAS proto-oncogene belongs to the GTPase family and among the 
RAS family of genes, two isoforms NRAS and KRAS are more frequently 
mutated in AML than third HRAS isoform [109]. Overall, RAS mutation 
is account about 10-25% of cases of AML and is enriched for in case 
having inv(16) (p13q22)/t(16;16)(p13;q22) or inv(3) (q21q26)/t(3;3)
(q21;q26) [110]. KRAS is most commonly mutated in malingnancies 
and mutation rate in all tumors is found to be 25-30%. NRAS mutations 
are frequently detected in patients with inv(16) and estimated to be 
9-14% in younger adults with CN-AML [14,18,111]. Point mutations 
are almost exclusively located at codons 12, 13, and 61 of RAS proto-
oncogene, resulting in loss of intrinsic GTPase activity and constitutive 
activation of the RAS protein [109]. HRAS mutations are extremely 
rare in myeloid leukemia and detected 11 to 25% of all cases [112]. The 
product of mutated RAS gene which is an abnormal RAS protein that 
is constitutively active can result in serious consequences, including 
cancers and other diseases [113]. Activated RAS anchores on the cell 
membrane and stimulates cell cycle regulation, differentiation and 
signal transduction RAS pathways [113]. 
RAS Prognostic Relevance
Several reports have suggested that AML patients harboring RAS 
mutations have worse, similar or more favorable clinical outcomes 
than those with wild type RAS genes [114]]. None of the larger studies 
has found an impact on prognosis, neither in the CN-AML subgroup 
nor in AML with other intermediate-risk karyotypes. Nevertheless, 
these mutations may represent a target for molecular therapy.
RAS Therapeutic Implication
The presence of RAS mutations seems to sensitize AML cells to 
high-dose cytarabine therapy in vivo and these patients when treated 
with chemotherapy alone probably benefit from high-dose cytarabine 
postremission treatment [115]. Wild type RAS proteins require post-
translational modifications by farnesyltransferase to get attached 
to binding sites in the cell membrane to become biologically active. 
Farnesyl transferase inhibitors (FTIs) are the best-studied class of Ras 
inhibitors in hematologic malignancies. However, RAS can escape FTI 
suppression and become activated through geranylgeranylation [116]. 
Tipifarnib, is the main FTI tested in AML patients. However, increased 
toxicity and suboptimal activity in elderly patients did not justify 
further investigation of this drug [117]. The same drug was also proven 
inactive in young AML patients [118]. Negative was also a phase 2 trial 
of lonafarnib, which is another FTI in patients with MDS or secondary 
AML [119].
RUNX1 Mutations
RUNX1 encodes a transcription factor that is essential for regulation 
of normal hematopoietic differentiation through dimerization with 
the CBF. CBF disruption by either translocations or point mutations 
is a common event in AML and MDS [120]. RUNX1 associated with 
undifferentiated morphology French-American-British (FAB) M0 and 
with specific chromosomal aberrations such as trisomy 21 and trisomy 
13. In a study of 156 cases with AML, highly selected for specific FAB 
and cytogenetic subgroups, RUNX1 mutations were detected in almost 
half (46%) of FAB M0 cases and in 80% of cases exhibiting trisomy 
13 [121]. Tang et al. reported frequency of RUNX1 mutations in an 
unbiased cohort of 470 AML cases was 13.2% [122]. In another study 
of 945 unselected younger adult patients with AML, RUNX1 mutations 
were detected with an overall incidence of 5.6% and mutations were 
associated with specific clinical and genetic characteristics and 
Citation: Tayyab M, Khan M, Iqbal Z, Altaf S, Noor Z, et al. (2014) Distinct Gene Mutations, their Prognostic Relevance and Molecularly Targeted 
Therapies in Acute Myeloid Leukemia (AML). J Cancer Sci Ther 6: 337-349. doi:10.4172/1948-5956.1000292
Volume 6(9) 337-349 (2014) - 343 J Cancer Sci Ther ISSN:1948-5956 JCST, an open access journal
predicted for inferior survival [123]. While study on 93 CN-AML 
patients demonstrated that RUNX1 found to be 16.1% and it were 
associated with a lower CR rate and with inferior DFS and OS than 
wild type patients [124]. Recurrent translocation involving RUNX1 
include t(8;21)(q22;q22) RUNX1-RUNX1T1 which is most frequent 
translocation 15-20% of all AML [125,126]. Somatic mutations 
clustering within the Runt domain of RUNX1 have been described in 
MDS and AML [127]. notably, inherited mutations of RUNX1 were 
identified as a cause of the autosomal familial platelet disorder that 
predisposes to the development of MDS and AML [128].
RUNX1 Prognostic Relevance
RUNX1 mutations occur with a relatively low incidence, it is 
difficult to show its prognostic impact, especially within the context 
of well-established strong prognostic molecular markers. In addition, 
the impact of allogeneic HSCT further complicated the evaluation as a 
prognostic marker by reducing the sample size after censoring patients 
who underwent transplantation.
RUNX1 Therapeutic Implication
RUNX family proteins were found to have an essential role in the 
regulation of gene expression by, for instance, temporal transcriptional 
repression and epigenetic silencing through chromatin alterations, 
especially in the context of chromosomal translocations [129]. These 
findings might have therapeutic implications as the RUNX1-associated 
gene deregulation and hematopoietic differentiation block might be 
effectively targeted by epigenetic therapeutic approaches.
IDH1/2 Mutations
IDH isoenzymes catalyse an essential step in the citric acid cycle 
that catalyzes conversion of isocitrate to α-ketoglutarate [130]. In 
mammalian cells three classes of IDH exist: nicotinamide adenine 
dinucleotide (NAD)-dependent IDH, mitochondrial nicotinamide 
adenine dinucleotide (NADP)-dependent IDH, and cytosolic NADP 
dependent IDH [131]. IDH1 gene is reside on chromosome band 2q33.3 
and its product is NADP-dependent and localized in cytoplasm and 
peroxisomes while IDH2 gene is located at chromosome band 15q26.1 
and encodes the mitochondrial NADP-dependent IDH2 enzyme [132]. 
Recurring mutations either in IDH1 and IDH2 were present in more 
than 70% of WHO grade 2 and 3 astrocytomas, oligodendrogliomas, 
and glioblastomas and in approximately 30% of patients with CN-
AML [133]. Both IDH1/2 mutants cause loss of the physiologic 
enzyme function and create a novel ability of the enzymes to convert 
α-ketoglutarate into 2- hydroxyglutarate, a putative oncometabolite 
[134]. Overproduction of 2-hydroxyglutarate due to IDH1 mutation 
has been associated with a high risk of brain tumors in patients with 
inborn errors [135].
Mutations of IDH1/2 were first reported in gliomas and were 
identified only in AML [26,27]. Interestingly, IDH1 and IDH2 
mutations are mutually exclusive and affect three specific arginine 
residues IDH1-R132, IDH2-R140 and IDH2-R170 [136]. Mutations 
affecting the IDH1-R132 and IDH2-R172 have been found both in 
brain tumors and AML, whereas those affecting the IDH2-R172 are 
private to AML. The aggregate frequency of these two mutations in 
AML is relatively high, approximately 15-20% of all patients with 
AML and 25-30% of patients with CN-AML harboring either IDH1or 
IDH2mutations respectively [27]. Different studies have reported the 
IDH1/2 mutational status in AML patients and a statistically significant 
co-occurrence with NPM1 and CEBPA mutations [137]. In the two 
consecutive studies correlations IDH1/2 mutations with outcome in 
AML, except for the IDH1/2 mutation enrichment in the NPM mutant 
group, it was reported that patients with the IDH-R140 mutation had 
an improved OS and decreased response rates. In contrast, IDH-R172 
mutations did not correlate to outcome or response to therapy, whereas 
presence of the IDH1-R132 mutation had an impact on worsened 
outcome in patients with the FLT3-WT genotype [138,139]. 
IDH1/2 Prognostic Relevance
Initial studies from larger and homogeneous series of patients 
indicate that IDH1 and possibly also IDH2-R140 mutations are 
significantly associated with NPM1 mutations and predict worse 
outcome for patients with mutated NPM1 without FLT3-ITD [26,27]. 
Interestingly, the distinct IDH2-R172 mutation is rarely associated 
with any of the other known prognostic mutations and seems to confer 
lower probability of achieving CR and possibly also inferior outcome 
[27]. Further investigation is needed to better define the prognostic 
impact of the IDH1/2 mutations in patients with AML.
IDH1/2 Therapeutic Implication
It is considered that small molecule inhibitors with a potential to 
stop the synthesis of 2- hydroxyglutarate could be developed given 
that IDH mutations lead to a gain-of-function mutation but up till 
now no such therapies have been discovered [140]. However it has 
been observed that IDH-mutant AMLs have a unique methylation 
profile characterized by global promoter hypermethylation, which 
provides these cases reasonable candidates for demethylation therapies 
[141]. Recent finding suggested that allogeneic HSCT may improve 
OS in younger patients with IDH mutations [137]. However, patient 
numbers who underwent allogeneic HSCT were small; the efficacy of 
allogeneic HSCT should be verified in large cohort of patients with 
IDH mutations 
JAK2 Mutations
The JAK2 encodes a non-receptor tyrosine kinase involved 
in relaying signals for hemopoietic cell growth, development and 
differentiation [142]. JAK proteins contains a family of four non-
receptor tyrosine kinases (JAK1, JAK2, JAK3 and Tyk2) that are closely 
associated with type I/II cytokine receptors. When activated through 
association to cell surface receptors they further phosphorylate and 
translocate STATs to the nucleus to regulate gene transcription [143]. 
Among the JAK family members JAK2 correlates with the IFN-1, IL-
6, 12/23 cytokine and erythropoietin receptors [144]. The JAK2V617F 
gain of function aberration in the cytoplasmic tyrosine kinase domain is 
frequently present in myeloid neoplasms [145]. The same mutation has 
been found in a small number of AML patients, more commonly in t(8; 
21) AML [146]. AML t(8; 21) patients having JAK2V617F in addition 
to KIT and FLT3 mutations have worse DFS compared to wild type 
JAK2 [147]. Beside the identified aberrations, a immunohistochemical 
study demonstrated that JAK2 phosphorylated in AML, whereas, 
increased p-JAK2 levels were found to be a predictor of worse response 
to chemotherapy (45% in patients with high p-JAK2 vs.78% in patients 
with low p-JAK2) and a factor of poor prognosis which validates its 
consideration as a therapeutic target in AML [148].
A study by Vicente et al. (2007) screened the 339 AML samples 
and found that 11 cases were positive for the JAK2-V617F mutation, 
overall frequency of the mutation was 3.2%, consistent with previous 
studies [146,149,150]. All mutated patients had either M1 or M2, 
demonstrating association with less-differentiated leukemias. There 
are few studies that describing the AML subtypes with mutated JAK2. 
However, the two studies conducted by Lee et al. and Steensma et al. 
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they investigated 113 and 162 AML patients, respectively, providing 
clinical data for the classification of the cases [146,149]. Vicente et al. 
found that V617F mutation was more common in secondary AML 
(8.3%) than in de novo AML (2.7%). Although they only analyzed four 
patients with M7, they did not find JAK2-V617F in these cases; Jelinek 
et al. found the mutation in 2 out of 11 AML-M7 patients and Steensma 
et al. in 1 out of 24, demonstrating that it would be interesting to study 
a large cohort of patients with megakaryocytic leukemia in order to 
understand the actual prevalence in this subgroup [149,151]. 
JAK2 Prognostic Relevance
In a previous study researcher analyzed the influence of the JAK2-
V617F mutation on prognosis, and they found that this mutation has 
no significant impact on the OS of patients with AML [150]. While 
recent study showed that in refractory anemia with ringed sideroblasts 
associated with sustained thrombocytosis, JAK2V617F mutation 
is frequent and associated with good prognosis, the clinical and 
prognostic impact of this mutation in other MDS is not clear [152].
JAK2 Therapeutic Implication
JAK inhibitors constitute a new class of drugs with activity in a 
wide range of diseases, primarily in myeloproliferative neoplasias 
(MPNs) and autoimmune disorders [153]. Ruxolitinib, the first JAK 
inhibitor that recently received marketing authorization by Food and 
Drug Administration (FDA) and European Medicines Agency for 
the treatment of myelofibrosis, is now investigated in patients with 
relapsed or refractory acute leukemia [154]. Several highly potent next 
generation JAK2/FLT3 inhibitors, such as pacritinib and lestaurtinib, 
entered clinical evaluation for patients with advanced myeloid 
malignancies [153]. First available data suggest that blockade of 
JAK2 in conjunction with FLT3 can enhance clinical benefit for AML 
patients harboring a FLT3-ITD mutation and provide a strong basis for 
a clinical evaluation of these targeted small molecule therapeutics in 
AML patients particularly to those who are resistant to FLT3 directed 
TKI therapy [66]. JAK inhibitors are among the first successful agents 
reaching clinical application. Ruxolitinib (Jakafi), a non-selective 
inhibitor of JAK1/2, has been approved by FDA for patients with 
intermediate to high risk primary or secondary myelofibrosis. Recent 
finding indicates that NS-018, a JAK2V671F inhibitor, will have 
the therapeutic benefits for MPN patients because it suppressed the 
growth of cells harboring JAK2V617F more strongly than that of cells 
harboring wild type JAK2 in myelofibrosis model mouse [155].
EZH2 Mutations
EZH2, located in 7q36.1, is another important gene associated 
with epigenetic regulation of transcription. EZH2 encodes enzymatic 
component of the polycomb repressive complex2, which is a Histone 
3 Lysine 27 (H3K27) methyltransferase, controls stem cell renewal 
by epigenetic alteration [156]. Over-expression of EZH2 has been 
described in both solid tumors and leukemia [157] and has been 
shown to be caused by the removal of transcriptional repression of 
specific microRNAs [157]. In myeloid neoplasms, mutations were 
found throughout the EZH2 and have been described in 10–13% of 
poor-prognosis MDS or MPN 13% of myelofibrosis , and 6% of MDS 
[158,159]. Zhang et al. (2012) found that almost half cases of early T-cell 
precursor ALL show aberrations in histone-modifying genes, including 
EZH2 [160]. While in AML, EZH2 mutations have been reported in 
a single case of acute myelomonocytic leukemia out of 143 cases 
screened, in only one case with pediatric AML and in a male with CN-
AML out of 50 cases [161]. Recently, EZH2 mutations were identified 
in 13/714 cases of AML patients and were found to be more frequent in 
males [162]. Recent findings indicates that EZH2 mutation in de novo 
AML as a recurrent genetic abnormality to be associated with lower 
blast percentage (21-30%) in bone marrow and -7/del(7q) [162]. The 
controversial data of over-expression of EZH2 in epithelial cancers, 
lymphomas and inactivating aberrations in myeloid malignancies 
revealed that mutations affecting the methylation of H3K27 may be 
tumor specific. Though, the causes, prevalence and clinical significance 
of somatic of EZH2 aberration in patients with AML remain largely 
unknown. 
EZH2 Prognostic Relevance
Due to rarity of EZH2 mutations in de novo AML, the prognostic 
significance of EZH2 mutations in AML is still not clear, and will 
require to be evaluated in larger cohorts of patients collected on multi-
center co-operative studies, However there no significant difference in 
EFS or OS was found between EZH2 mutated patients and wild type in 
the recent study [162].
EZH2 Therapeutic Implication
Development of selective inhibitors of histone methyltransferases, 
such as EZH2 have just started. An S-adenosylhomocysteine hydrolase 
inhibitor known as 3-Deazaneplanocin A (DZNep) has beenobserved 
to evoke efficient apoptosis in cancer cells but not in normal cells and 
to significantly reduce cellular levels of PRC2 components for instance 
EZH2 while reducing associated histone H3K27 methylation [163]. 
Combined DZNep and panobinostat therapy induced more EZH2 
reduction and more apoptosis in AML cells compared to normal 
CD34(+) bone marrow progenitor cells [164]. This compound has not 
reached yet the clinical trial setting. An EZH2-selective small-molecule 
inhibitor EI1, which competitively binds to the S-adenosylmethionine 
pocket of the EZH2 SET domain in both wild type and Tyr641 mutated 
cells [165]. This inhibition of histone H3K27me3 led to G1 growth 
arrest, apoptosis and differentiation of EZH2 mutant cells into memory 
B cells. Recent findings revealed that Two compounds, EPZ005687 
and GSK126, independently identified by high-throughput screening, 
inhibit EZH2 using same mechanism as described for EI1 [166].
PLK1 Mutations
PLK belongs to family of four serine/threonine protein kinases that 
are vital regulators of cell cycle regulation, mitosis, cytokinesis, response 
to DNA damage and programmed cell death [167]. They attach and 
phosphorylate proteins that are previously phosphorylated on a specific 
motif identified by the POLO box domains and interact with Aurora 
kinases [168]. The most well characterized member of PLK family is 
PLK1 and considered to be a key player of cell-cycle progression during 
mitosis significantly enhancing the regulation of cells via mitosis. PLK1 
activates the mitotic licensing of centriole duplication in human cells 
and also DNA replication under unfavorable conditions, and anti-
apoptotic activity via phosphorylation of Bcl-xL [169]. Overexressed 
PLK1 is thought to behave as oncoprotein [170]. PLK1 is frequently 
found over-expressed in heavily of samples from AML patients as 
compared to normal progenitors [171]. 
PLK1 Therapeutic Implication
Early studies that PLK1 depletion could evoke cell death in cancer 
cells led to discovery and progression of PLK1 inhibitors having potent 
antitumor function against leukemia [172]. Moreover, PLK inhibition 
is now found to be a promising strategy for AML treatment when 
combined with conventional anti-leukemic chemotherapy [173]. The 
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first PLK1 inhibitor BI 2536 which was used in clinical development in 
AML having promising initial outcomes revealed interesting clinical 
activity in patients with relapsed and treatment refractory AML in 
clinical investigation. In addition, Its successor volasertib (BI 6727) 
showed more approving toxicity profile and potent antileukemic role 
as monotherapy and in combination with low dose aracytin in majority 
of pretreated AML patients and was used in phase III clinical trial 
[174,175].
Conclusion
It has been well recognized that AML is a very aggressive 
heterogeneous disease at cytogenetic and molecular genetics level 
and classified by recurrent genetic aberrations that define subgroups 
of different biological and clinical features. Key discoveries have been 
made over a decade that has contributed to a better understanding of 
the molecular pathogenesis and to an improvement of the classification 
of AML. Moreover, mutations in genes such as NPM1, FLT3 or CEBPA 
have been found to provide significant prognostic information, and 
currently it is suggested to include mutation analysis of these genes in 
the early diagnostic work-up of AML patient, particularly in the context 
of a clinical study. However, we have only just started to untangle the 
huge genetic diversity of AML. In addition, the discovery of highly 
recurrent mutations in gene such as RUNX1, IDH1/2, EZH2 and PLK1 
may provide a new tool for the classification of intermediate-risk AML. 
If these studies are reproduced in other progression, clinical trials 
designed to evaluate the impact of initial intensification of treatment 
in AML patients with these alterations may be accepted. Steady 
advancement in genomics technology will lead to the characterization 
of further gene mutations and novel mechanisms of leukemogenesis. 
These specified insights into leukemogenic aberrations and pathways 
provide the basis for the compounds development and strategies 
to target genetic changes or epigenetic pathways. Compounds like 
FLT3-tyrosine kinase inhibitors for FLT3-mutated cases, or imatinib 
for KIT-mutated cases are in part already transferred to clinical 
application while others are still being analyzed in preclinical trials. 
Furthermore, molecular techniques such as high-throughput DNA 
sequence analysis in large numbers of primary patient samples will 
become available at an reasonable cost, which may consequence in the 
development of complete, disease and allele-specific gene aberrations 
profiling strategies. Lastly, innovative functional genetic approaches, 
such as large-scale RNA interference, have immense potential for the 
discovery of novel oncogenes. It is anticipated that the information 
receiving from these studies will also ultimately result in development 
of efficient molecular targeted therapies. Therefore, the progression of 
new diagnostic techniques and research for novel therapeutic targets 
should be considered as essential element, since only their perfect 
interaction will lead to targeted treatment for AML patients.
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